Nucleoside-modified RNA for inducing an adaptive immune response

Patent metadata

Field	Value
Publication number	US-12138305-B2
Application number	US-202217705837-A
Country	US
Kind code	B2
Filing date	Mar 28, 2022
Priority date	Apr 27, 2015
Publication date	Nov 12, 2024
Grant date	Nov 12, 2024

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

First claim

What is claimed is:

1. A composition for inducing an adaptive immune response in a subject, the composition comprising at least one nucleoside-modified RNA encoding at least one influenza hemagglutinin (HA) antigen, wherein the mRNA molecule encoding the influenza antigen comprises a sequence selected from SEQ ID NO:5 and SEQ ID NO:8.

2. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises pseudouridine.

3. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises 1-methyl-pseudouridine.

4. The composition of claim 1 , wherein the composition further comprises an adjuvant.

5. The composition of claim 1 , wherein the at least one nucleoside-modified RNA further encodes at least one adjuvant.

6. The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

7. The composition of claim 6 , wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

8. The composition of claim 1 , wherein the composition is a vaccine.

9. A method of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

10. The method of claim 9 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, and intramuscular.

11. The method of claim 9 , wherein the method comprises a single administration of the composition.

12. The method of claim 9 , wherein the method comprises a multiple administrations of the composition.

13. The method of claim 9 , wherein the method treats an influenza infection.

Assignees

• Univ Pennsylvania

Inventors

• Weissman Drew
• Pardi Norbert

Classifications

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• A61K31/712

  Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title

• A61K31/7115

  Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title